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Malignancy Rate in Thyroid Nodules
Classified as Bethesda Category III (AUS/FLUS)
Allen S. Ho,1 Evan E. Sarti,1 Kunal S. Jain,1 Hangjun Wang,2 Iain J. Nixon,1 Ashok R. Shaha,1
Jatin P. Shah,1 Dennis H. Kraus,3 Ronald Ghossein,2 Stephanie A. Fish,4 Richard J. Wong,1
Oscar Lin,2 and Luc G.T. Morris1

Background: The Bethesda System for Reporting Thyroid Cytopathology is the standard for interpreting fine
needle aspiration (FNA) specimens. The ‘‘atypia of undetermined significance/follicular lesion of undetermined
significance’’ (AUS/FLUS) category, known as Bethesda Category III, has been ascribed a malignancy risk of
5–15%, but the probability of malignancy in AUS/FLUS specimens remains unclear. Our objective was to
determine the risk of malignancy in thyroid FNAs categorized as AUS/FLUS at a comprehensive cancer center.
Methods: The management of 541 AUS/FLUS thyroid nodule patients treated at Memorial Sloan–Kettering
Cancer Center between 2008 and 2011 was analyzed. Clinical and radiologic features were examined as predictors
for surgery. Target AUS/FLUS nodules were correlated with surgical pathology.
Results: Of patients with an FNA initially categorized as AUS/FLUS, 64.7% (350/541) underwent immediate
surgery, 17.7% (96/541) had repeat FNA, and 17.6% (95/541) were observed. Repeat FNA cytology was unsatisfactory in 5.2% (5/96), benign in 42.7% (41/96), AUS/FLUS in 38.5% (37/96), suspicious for follicular
neoplasm in 5.2% (5/96), suspicious for malignancy in 4.2% (4/96), and malignant in 4.2% (4/96). Of nodules
with two consecutive AUS/FLUS diagnoses that were resected, 26.3% (5/19) were malignant. Among all index
AUS/FLUS nodules (triaged to surgery, repeat FNA, or observation), malignancy was confirmed on surgical
pathology in 26.6% [CI 22.4–31.3]. Among AUS/FLUS nodules triaged to surgery, the malignancy rate was
37.8% [CI 33.1–42.8]. Incidental cancers were found in 22.3% of patients. On univariate logistic regression
analysis, factors associated with triage to surgery were younger patient age ( p < 0.0001), increasing nodule size
( p < 0.0001), and nodule hypervascularity ( p = 0.032).
Conclusions: In patients presenting to a comprehensive cancer center, malignancy rates in nodules with AUS/
FLUS cytology are higher than previously estimated, with 26.6–37.8% of AUS/FLUS nodules harboring cancer.
These data imply that Bethesda Category III nodules in some practice settings may have a higher risk of malignancy
than traditionally believed, and that guidelines recommending repeat FNA or observation merit reconsideration.

Introduction

F

ine-needle aspiration (FNA) plays an instrumental
role in the workup of the thyroid nodule by estimating
the risk of malignancy and thereby assisting rational triage
of patients to surgery or observation. While only approximately 5% of thyroid nodules harbor malignancy, the use of
FNA has permitted highly effective risk stratification, such
that more than 50% of surgically resected nodules ultimately reveal cancer (1). Accordingly, this has effectively
reduced the number of unnecessary surgeries and their associated sequelae.

Despite the benefits of FNA, cytopathology reports in the
past have been ambiguous or difficult to interpret. Vague
descriptors such as ‘‘atypical,’’ ‘‘indeterminate,’’ or ‘‘cannot
exclude’’ have been demonstrated to confuse management
(2). These terms are perceived differently by pathologists,
endocrinologists, and surgeons, especially between institutions (3,4). Such shortcomings were the impetus for the
Bethesda System for Reporting Thyroid Cytopathology,
which standardized thyroid FNA results into six diagnostic
categories and has become the accepted mode of communication between the various specialties caring for thyroid
nodule patients (5,6). Implementation of the Bethesda
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System for Reporting Thyroid Cytopathology has improved
the quality of FNA reporting, promoting greater transparency
and fewer unwarranted thyroidectomies (7).
However, Bethesda Category III (‘‘atypia of unknown
significance’’ [AUS], also termed ‘‘follicular lesion of unknown significance’’ [FLUS]) has generated controversy due
to inconsistent usage across different clinicians and institutions. AUS/FLUS was defined for use as a category of last
resort, with the expectation that 7% or fewer of FNAs would
receive this diagnosis (5,6). The Bethesda consensus publication estimates that such a nodule would be associated with
a low risk of malignancy (5–15%) and, in the absence of other
suspicious features, could be managed with a repeat FNA.
Conversely, Bethesda Category IV (follicular neoplasm or
suspicious for follicular neoplasm) is thought to warrant
surgery due to an estimated 15–30% risk of malignancy. In
contrast to the Bethesda recommendations, the guidelines
released by the American Association of Clinical Endocrinologists/Associazione Medici Endocrinologi/European
Thyroid Association (AACE/AME/ETA) Task Force combine Bethesda Categories III and IV (both defined as indeterminate) (8,9). This group recommends surgery in most
instances, with observation only in cases with favorable
clinical, cytologic, and sonographic features.
The 5–15% risk of malignancy from Bethesda Category III
nodules remains an initial approximation, with the precise
incidence variable among institutions (5,6,10,11). The
emergence and FDA approval of molecular testing also
suggests the need to reexamine this percentage and its associated recommendation. The actual risk of malignancy is
difficult to determine, since a pathologic diagnosis is only
available in the subset of patients selected for surgery. Previous studies have not strictly followed Bethesda guidelines,
have included incidental carcinomas in rates of malignancy,
or have retrospectively classified specimens under the Bethesda System for Reporting Thyroid Cytopathology (12–16).
Here, we describe the experience of a large cohort of patients
with Bethesda Category III (AUS/FLUS) at a comprehensive
cancer center, where thyroid nodules were classified at the
time of care under the Bethesda System for Reporting Thyroid
Cytopathology.
Methods

We reviewed the records of all patients with thyroid
nodules classified by the Bethesda System between 2008
and 2011 at Memorial Sloan–Kettering Cancer Center
(MSKCC). This includes FNAs performed at the MSKCC or
outside FNAs interpreted by MSKCC cytopathologists. All
patients had thyroid ultrasound records available. AUS/
FLUS patients with additional biopsy-proven thyroid malignancy, or previous FNAs demonstrating Bethesda Class
IV–VI were excluded, as were those without documented
follow-up. This study was deemed exempt by the MSKCC
Institutional Review Board.
FNAs were performed by a dedicated radiologist using a
25- or 27-gauge needle under ultrasound guidance, typically
with one to four passes. An air-dried slide was stained with a
modified Giemsa stain for adequacy assessment. The remaining slides were alcohol-fixed and stained with hematoxylin and eosin. The needle was then rinsed in CytoLyt
(Hologic, Marlborough, MA), and Papanicolaou-stained
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ThinPrep slides were prepared using the ThinPrep 2000
(Hologic, Marlborough, MA). Cell block preparations were
made when adequate material was available. On-site assessment for adequacy was routinely performed.
All reports followed the diagnostic scheme proposed by
the 2007 National Cancer Institute Thyroid FNA State of the
Science Conference Guidelines (10) and the subsequent
Bethesda System for Reporting Thyroid Cytopathology (5).
Additional cytologic substratification at our institution was
also performed (17). Operative criteria included large
multinodular goiter, concerning sonographic features (17),
enlarging nodule size, clinical suspicion, or patient/physician
preference. Patients with two consecutive AUS/FLUS diagnoses were recommended to undergo surgery for diagnostic
and therapeutic purposes.
For patients undergoing surgery, AUS/FLUS nodules were
identified by correlating cytology reports with ultrasound and
pathology reports. For pathologic analysis, tumor size was
considered the maximum diameter within the resected gland.
Mitotic rate was ascertained by counting 10 high-power fields
(400 ·) with a U-DO microscope (Olympus, Center Valley,
PA). Incidental carcinomas (including microcarcinomas)
distinct from the target nodule were categorized and analyzed
separately.
Estimates of the rate of malignancy in thyroid nodules are
subject to several biases, as not all nodules undergo surgical
resection and confirmatory pathologic analysis. Therefore,
we determined the conceivable range of malignancy rates.
The lower-bound estimate was calculated by dividing the
number of confirmed malignancies by the total number of
AUS/FLUS nodules, whether triaged to surgery, repeat FNA,
or observation. The assumption that all observed (nonoperated) AUS/FLUS nodules were benign is subject to
verification bias, and therefore underestimates the prevalence
of malignancy. The upper-bound estimate was calculated by
dividing the number of confirmed malignancies by the
number of AUS/FLUS nodules selected to undergo surgery.
As nodules selected for surgery may have other clinical or
ultrasonographic features that increase suspicion, this number is subject to selection bias, overestimating the prevalence
of malignancy. The true prevalence is likely to lie between
the lower- and upper-bound approximations.
Clinical and ultrasonographic variables were recorded and
evaluated for their association with surgery, including age,
sex, size, irregular margins, hypoechogenicity, hypervascularity, and calcifications. Logistic regression analysis was
performed using SPSS v21 (IBM Corp., Armonk, NY).
Comparative analyses were performed with chi-square
analysis with Yates correction. All p-values were predetermined to be two-sided, with the level of significance set
at p < 0.05. Confidence intervals (CI) were calculated using
the Poisson distribution.
Results

Collectively, 8.0% (709/8862) of all thyroid FNAs performed during the study period were classified as AUS/FLUS,
approximating Bethesda System for Reporting Thyroid
Cytopathology guidelines (Table 1 and Fig. 1). Of the 709
patients with AUS/FLUS on initial FNA, 541 had documented
follow-up, with a median period of 14 months. The median age
of AUS/FLUS patients was 54.0 years, with 80.4% of patients
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Table 1. Cohort FNA Classification
by Bethesda Category

Bethesda Category
I (unsatisfactory)
II (benign)
III (AUS/FLUS)
IV (suspicious for
follicular neoplasm)
V (suspicious for malignancy)
VI (malignant)

Bethesda
expected
incidence

Cohort
incidence

< 10%
60–70%
< 7%
N/A

3.2%
72.9%
8.0%
2.8%

N/A
3–7%

4.6%
8.5%

AUS/FLUS, atypia of undetermined significance/follicular lesion
of undetermined significance; FNA, fine-needle aspiration; N/A, not
applicable.

being female. The median nodule size was 1.9 cm. From this
cohort, 64.7% (350/541) underwent immediate surgery, 17.7%
(96/541) underwent repeat FNA, and 17.6% (95/541) were
observed. The mean nodule sizes for these subgroups were
2.3 cm, 2.0 cm, and 1.9 cm respectively.
On ultrasound, 11.5% of nodules were complex, 12.4%
harbored microcalcifications, 19.4% had hypervascular features, and 21.4% were hypoechoic. In our cohort, 9.9% (51/
541) of nodules were identified as positron emission tomography/computed tomography (PET/CT) scan incidentalomas,
of which 13.7% (7/51) were found to be malignant. Additionally, 61.9% (335/541) were outside referrals (29.6%
were malignant), while 38.1% (206/541) were diagnosed internally at MSKCC (21.8% were malignant). Substratification
of AUS/FLUS nodules based on cytologic features is listed
in Table 2.

Repeat FNA is recommended by the Bethesda System for
Reporting Thyroid Cytopathology to help delineate clinical
decision making in AUS/FLUS nodules (Table 3). Of the 96
nodules undergoing repeat FNA, the second FNA was unsatisfactory (Category I) in 5.2% (5/96), benign (Category II)
in 42.7% (41/96), AUS/FLUS (Category III) in 38.5% (37/
96), suspicious for neoplasm (Category IV) in 5.2% (5/96),
suspicious for malignancy (Category V) in 4.2% (4/96), and
malignant (Category VI) in 4.2% (4/96; Fig. 2). Of those with
a benign FNA who still underwent surgery (2/41), 0% (0/2)
were malignant. Of those nodules with two consecutive AUS/
FLUS diagnoses, 51.4% (19/37) went on to surgery and
26.3% (5/19) were found to be malignant.
On univariate logistic regression analysis, factors associated with triage to surgery were increasing nodule size
( p < 0.0001), younger patient age ( p < 0.0001), and presence
of hypervascularity ( p = 0.032). Sex, hypoechogenicity, infiltrative margins, and calcifications were not found to be
predictive. On multivariable analysis, none of the above
variables was found to be significant.
Risk of malignancy among patients with AUS/FLUS
nodules triaged to surgery (upper-bound estimate)

Of the 350 (64.7%) nodules with AUS/FLUS cytopathology that went on to immediate surgery, the rate of
malignancy was 38.6% (135/350). Including the 31 nodules
that were resected (after repeat FNA), the rate of malignancy for all patients triaged to surgery was 37.8% (144/
381) [CI 33.1–42.8]. These estimates represent the upper
bound of the true incidence rate. The vast majority of malignant surgical specimens comprised papillary thyroid
carcinoma, either classical or other subtypes (86.8%).
Follicular variant of papillary thyroid carcinoma comprised

FIG. 1. Flow schematic of atypia of undetermined significance/follicular lesion of undetermined significance (AUS/
FLUS) thyroid nodule patients managed between 2008 and 2011. Malignancy rates shown are specific to the targeted AUS/
FLUS nodule, excluding incidental cancers or concurrent nodules.
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Table 2. Cytologic Substratification of Bethesda III Nodules
Benigna

AUS/FLUS cases with surgery
AUS/FLUS—NOS (n = 218)
AUS/FLUS—favor benign (n = 13)
AUS/FLUS—cannot exclude PTC (n = 28)
AUS/FLUS—cannot exclude Hürthle cell neoplasm (n = 44)
AUS/FLUS—cannot exclude follicular neoplasm (n = 78)

41.3%
76.9%
28.6%
34.1%
24.4%

[CI
[CI
[CI
[CI
[CI

36.0–46.6]
69.2–84.6]
9.4–47.8]
20.5–47.7]
11.9–36.9]

Malignant
36.2%
7.7%
53.6%
29.5%
56.4%

[CI
[CI
[CI
[CI
[CI

29.4–42.5]
1.9–36.0]
33.9–72.1]
16.8–45.2]
44.7–67.6]

a
Excludes nonmalignant neoplasms.
CI, confidence interval; PTC, papillary thyroid carcinoma; NOS, not otherwise specified.

48.8% of the papillary thyroid cancers. The majority of
benign surgical specimens consisted of nodular hyperplasia
(51.9%; Fig. 3).
There were an additional 85 patients with separate incidental thyroid cancers identified, 76 of which were papillary
microcarcinomas (89.4%). There were 11 cases with dual
primary and incidental cancers. If incidental cancers are included, the cumulative rate of malignancy in resected glands
(counting AUS/FLUS cancerous nodules and incidental
carcinomas) was 57.2% (218/381).
Risk of malignancy among all patients with AUS/FLUS
nodules (lower-bound estimate)

The incidence of malignancy among all patients with a
nodule classified as AUS/FLUS, whether triaged to surgery
or not, was 26.6% (144/541) [CI 22.4–31.3]. This estimate
represents the lower bound of the true incidence rate, as it
assumes that all observed nodules are benign.
Risk of malignancy among patients with consecutive
AUS/FLUS FNAs

The upper-bound estimate of patients with two successive
FNAs showing AUS/FLUS was 26.3% (5/19). Assuming the
observed patients had benign nodules, the lower-bound estimate was 13.5% (5/37).
Discussion

The Bethesda System for Reporting Thyroid Cytopathology has greatly facilitated the standardization of FNA reporting. By clarifying ambiguous language and riskstratifying patients, it has enabled more precise decision
making when selecting patients for surgery. Its rationale is
also based upon multidisciplinary consensus and a reasonable
incidence of malignancy. For instance, the recommendation

for clinical follow-up for Bethesda Category II (benign) is
based on a 0–3% risk of malignancy, while the recommendation for surgery for Bethesda Category V (suspicious for
malignancy) is based on a 60–75% risk (5,6).
However, the appropriate level of risk to assign to
Bethesda Category III (AUS/FLUS) nodules remains ambiguous, with some arguing against the need for equivocation in a system designed to minimize it (4,14). Shi et al.
found that eliminating the use of AUS/FLUS as a diagnosis considerably decreased FNA sensitivity, increasing
false positive and false negative rates while escalating interand intra-observer variability (14). Nevertheless, the exact
risk of malignancy has been unclear, as many AUS/FLUS
nodules are observed with no pathologic confirmation
available.
This study examined the histologic outcomes in a large
number of AUS/FLUS nodule patients classified with Bethesda criteria and treated at a comprehensive cancer center.
The heterogeneity of the AUS/FLUS diagnosis has led to
this cytopathologic diagnosis being rendered at rates of up
to 18% in some series (12,16), suggesting high variability
across institutions. Unlike previous reports, the incidence
of AUS/FLUS diagnoses in this study was similar to the
Bethesda System for Reporting Thyroid Cytopathology recommended rate of 7%, indicating that the results are
comparable with its intent. As a high percentage of patients
underwent immediate surgery after FNA, this cohort distinctively provides pathological confirmation for nodules
with an initial AUS/FLUS diagnosis.
Before proceeding, it is important to mention a number of
caveats pertaining to our data. Any estimate of the risk of
malignancy in indeterminate thyroid nodules is limited by the
fact that not all nodules undergo surgery with resultant
pathologic analysis. There are a number of factors, described
in detail below, that may influence the decision to refer a
patient with a Bethesda III thyroid nodule to a specific

Table 3. Results of Second Fine-Needle Aspiration After Initial AUS/FLUS Diagnosis
Bethesda Category
I (unsatisfactory)
II (benign)
III (AUS/FLUS)
IV (suspicious for follicular neoplasm)
V (suspicious for malignancy)
VI (malignant)
Total
a

Second FNA (n)
5
41
37
5
4
4

(5.2%)
(42.7%)
(38.5%)
(5.2%)
(4.2%)
(4.2%)a
96

Surgery (n)
2
2
19
4
2
2

Papillary thyroid cancer · 3, lymphoma · 1.
2 patients (lymphoma, papillary thyroid cancer on FNA) did not undergo surgery.

b

(40.0%)
(4.9%)
(51.3%)
(80.0%)
(50.0%)
(50.0%)b
31

Cancer in specimen (n)
0
0
5
2
0
2

(0.0%)
(0.0%)
(26.3%)
(50.0%)
(0.0%)
(100.0%)
9
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FIG. 2. Repeat fine-needle aspiration (FNA) results after
initial AUS/FLUS diagnosis. A second (consecutive) AUS/
FLUS diagnosis was found in 38.5% of patients, while
42.7% of repeat FNAs were benign. AUS/FLUS, Atypia of
Undetermined Significance/Follicular Lesion of Undetermined Significance (Bethesda Category III); SFN, suspicious for neoplasm (Bethesda Category IV); SFM,
suspicious for malignancy (Bethesda Category V).
institution and, furthermore, that may influence the decision
to triage a patient to surgical resection. These types of ‘‘referral bias’’ and ‘‘selection bias,’’ if present, tend to enrich
the prevalence of malignancy within Bethesda III nodules.
For these reasons, rather than calculating one malignancy
rate, we have instead provided both lower- and upper-bound
estimates of the prevalence of malignancy in this cohort.
Furthermore, we have carefully examined the characteristics
of our cohort, and not found evidence of disproportionate bias
toward the higher-risk end of the spectrum. Nevertheless, the
rate of malignancy in Bethesda III nodules does vary among
institutions, and is likely to be higher at a referral center such
as ours.
Accordingly, we estimate that the risk of malignancy for
an AUS/FLUS nodule is between 26.6% and 37.8%, notably
higher than the 5–15% approximation. Such numbers may be
elevated enough to justify surgery, not unlike the recommendation for lobectomy based upon Bethesda Category IV
risk (15–30%; Fig. 4). Collectively, our results suggest that
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AUS/FLUS nodules, even at the low ‘‘last resort’’ incidence
suggested by the Bethesda System for Reporting Thyroid
Cytopathology, may warrant reconsideration of current recommendations. However, we caution that our results may not
be generalizable to AUS/FLUS cohorts substantially different from that described here.
Other published cohorts of smaller size have suggested
wide-ranging malignancy risk for AUS/FLUS nodules. Parengi et al. observed an incidence of 16% [CI 10.2–23.6] (18),
while VanderLaan et al. reported a prevalence of 46% [CI
36.8–56.1] (16). These and other outcomes have been confounded by study periods predating the Bethesda System for
Reporting Thyroid Cytopathology, an incidence of AUS/
FLUS diagnoses that is higher than the 7% expected, and, in
some cases, inflation of the malignancy rate with incidental
cancers (12–16). Differences may also relate to random
variation or institutional differences in pathologic interpretation. Nonetheless, the confidence intervals of these series
largely overlap those of the current study, further supporting
the higher than expected cancer incidence in AUS/FLUS.
The limitations of cytology underscore the importance of
emerging molecular assays in determining the need for surgical intervention. Recent advancements in a gene expression
classifier assay using FNA material have demonstrated high
negative predictive value in cytologically indeterminate
thyroid nodules (Bethesda Classes III–V) (19). As our study
supports that the pretest probability of malignancy for AUS/
FLUS nodules is >5–15%, such molecular testing may become instrumental to rule out cancer judiciously and reduce
unnecessary thyroidectomies. However, a higher pretest
probability of malignancy, such as was observed in this cohort, may limit the utility of certain molecular classifiers to
reliably determine benignancy (20). It is therefore critical to
estimate the rates of malignancy at each insititution.
Although the Bethesda System for Reporting Thyroid
Cytopathology recommends repeat FNA for AUS/FLUS, the
American Thyroid Association (ATA) is less clear (17),
while the AACE/AME/ETA guidelines recommend against
repeat FNA due to the possibility of confounding results
(8,9). In this study, the incidence of malignancy after one
AUS/FLUS diagnosis was notably no different from the incidence of cancer after two ( p = 0.98), corresponding to
findings by VanderLaan et al. (16). However, the repeat FNA
was not indeterminate in 56.3% (54/96) of our patients,
raising the question of whether the Bethesda recommendation for repeat FNA may be beneficial in some cases. The

FIG. 3. Histologic outcomes for AUS/FLUS patients triaged to surgery. AUS/FLUS nodules with a malignant diagnosis
most commonly harbored papillary thyroid carcinoma. CA, cancer; diff., differentiated.
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FIG. 4. Adjusted malignancy risk of thyroid nodules by Bethesda classification. The incidence of malignancy for AUS/
FLUS observed is higher than that estimated by the Bethesda System for Reporting Thyroid Cytopathology, and falls within
the range where surgical intervention is recommended (Bethesda Category IV). *Conservative estimate assuming all
observed/nonsurgical patients are benign. {Aggressive estimate considering only nodules triaged to surgery. MSKCC,
Memorial Sloan-Kettering Cancer Center; SFN, suspicious for neoplasm; SFM, suspicious for malignancy.
accuracy of the diagnosis rendered on repeat FNA may not be
clear. In the two series by Vanderlaan et al. and Renshaw
et al., patients with a Bethesda Category III FNA followed by
a benign FNA (and who went on to surgery) had malignant
disease in 9.4% (3/32) and 28.5% (2/7) of cases respectively
(16,21). In our series, 0% (0/2) harbored malignancy, but in
actuality most of these patients (39/41) never went on to
surgery. Given the small numbers in these subsets, the issue
of repeat FNA remains of uncertain value: it is not clear
whether a benign diagnosis on repeat FNA should be
weighted more or less heavily than the index AUS/FLUS
diagnosis. The risk of malignancy in a nodule with separate
needle biopsies interpreted as AUS/FLUS and then benign
may lie somewhere in between the risk of malignancy for the
respective individual categories.
Substratification of thyroid nodules has generated growing
interest (21–25), with potential implications for cytologybased risk stratification. Horne et al. subclassified 106 nodules into INa (predominant microfollicular architecture; 7%
malignancy rate) and INb (nuclear atypia; 56% malignancy
rate) categories (23). These results suggest that indeterminate
nodules with nuclear atypia could be at substantially higher
risk for malignancy. In our cohort, similar substratification
was not informative: the risk of malignancy in ‘‘AUS/
FLUS—cannot exclude follicular neoplasm’’ (similar to INa)
was 56.4%, while ‘‘AUS/FLUS—cannot exclude PTC’’
(similar to INb) risk was 53.6% (Table 2). Only 7.3% of
nodules in our cohort had features corresponding to the
higher-risk ‘‘INb’’ category, suggesting this subgroup may be
less common. The predominant subcategory identified in our
study was ‘‘AUS/FLUS—not otherwise specified’’ (57.2% of
patients), which had a 36.2% malignancy rate.
Limitations of the current study include lack of extended
follow-up, resulting in possible verification bias. Given the
nature of AUS/FLUS management, some observed nodules

may never show clinical signs of malignancy and yet may
harbor cancer. This would lead our lower-bound estimate to
be a significant underestimate of the prevalence of malignancy. The indolent nature of many thyroid cancers makes
this scenario very possible. Conversely, the nodules with
pathologic specimens for analysis are skewed due to the selection of those patients for surgery: resection could have
been chosen due to unfavorable clinical or radiographic
features that elevate the likelihood of malignancy. Although
various sonographic factors are known predictors of malignancy (17), only hypervascularity, younger age, and increasing size were significant predictors of surgery on
univariate analysis. Size in particular may be a major factor,
as a 4 cm AUS/FLUS nodule will likely be managed differently from a 1 cm AUS/FLUS nodule. However, none of
these was significant on multivariable analysis. Our institutional philosophy of triaging most AUS/FLUS patients to
surgery may have superseded these factors. Nonetheless,
Nagarkatti et al. similarly found that ultrasonographic features such as microcalcifications, irregular margins, and hypoechogenicity were not associated with a decision to
perform surgery (18). Such findings suggest that imaging
features predictive for malignancy in all thyroid nodules do
not extend to those predictive for surgery, especially in an
AUS/FLUS nodule subset.
Importantly, certain higher-risk AUS/FLUS subgroups
may be enriched at a cancer center, with such a referral bias
potentially inflating the malignancy rate. The elevated cancer
incidence could also be ascribed to a lower diagnostic
threshold whereby higher-risk Bethesda Categories (IV–VI)
are called AUS/FLUS at our institution. The median age, sex
breakdown, and median nodule size of patients in this
MSKCC cohort are comparable to other reports (19,23). For
example, in the molecular classifier study by Alexander et al.
(19) that studied 577 patients with indeterminate nodules
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(predominantly from community physicians), median age was
52.8 years (54.0 years in this cohort), 78.2% were female
(80.4% in this cohort), and median nodule size was 2.2 cm
(1.9 cm in this cohort). Analysis of all FNAs performed at our
institution during the study period found that the overall
breakdown of Bethesda Categories was not skewed toward
higher-risk categories (Table 1). Moreover, within the AUS/
FLUS cohort itself, the higher-risk subgroups with a higher
probability of cancer (‘‘AUS/FLUS—cannot rule out PTC,’’
corresponding to the INb category of Horne et al. (23))
comprised only 7.3% of our cohort (Table 2). The incidence
of PET/CT incidentalomas, which may reflect a higher rate
of malignancy, was also not inordinately high (9.9%), and
the incidence of cancer within this PET/CT subgroup was
modest (13.7%). Nevertheless, we cannot definitely rule out
the potential for other, unmeasured sources of bias, and
therefore have deliberately described lower- and upperbound estimates to address such uncertainty. As the prevalence of malignancy may vary between institutions, we
believe there is value to presenting our analysis with such
a range.
Conclusion

The risk of malignancy in AUS/FLUS thyroid nodules as
defined by the Bethesda System for Reporting Thyroid
Cytopathology is higher than estimated, with an estimated
prevalence of 26.6–37.8%. The incidence of malignancy after an index AUS/FLUS diagnosis is also similar to the rate
after consecutive AUS/FLUS diagnoses, suggesting that repeat FNA may not have clear utility in clinical decision
making. The limitations of FNA cytology imply that other
diagnostic options, including molecular assays, may be
valuable to delineate risk further and assist clinicians in
identifying low-risk patients who may not require surgery.
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